FOXA3 and asthma: Thus, our results suggest that the greatest impact of the FOXA3 variant on asthma risk will be among T2-low subjects, where possession of the high expressing genotype can drive FOXA3 expression levels up to a risk-conferring level, already eclipsed among T2-high subjects.